FDA Approves First New Adjuvant Treatment for Stage III Melanoma Patients in 20 Years
October 27, 2015Statement from Tim Turnham, Executive Director, Melanoma Research Foundation Washington, D.C.—Today the Food and Drug Administration (FDA) approved ipilimumab (Yervoy) for use as a way to lower the risk of recurrence for melanoma patients …
FDA Approves Talimogene Laherparepvec (T-VEC) for Advanced Melanoma
October 27, 2015Today the FDA approved Amgen’s drug, Imlygic (Talimogene Laherparepvec or T-VEC), for the treatment of unresectable Stage IIIB, IIIC or IV metastatic melanoma, bringing a novel immunotherapy to people with advanced melanoma, many of whom have limited t …
Guest Post: Dr. Richard Carvajal – #CUREOM Unite!
October 14, 2015For the last decade, Dr. Richard Carvajal has dedicated his career to the research and treatment of rare cancers like ocular melanoma (OM) and understands the need for more funding to drive research breakthroughs in the field. Dr. Carvajal currently se …
Guest Post: Connie’s Story
October 6, 2015Guest blogger Connie Popp shares her experience as an ocular melanoma caregiver, advocate and participant in Miles for Melanoma in support of the CURE OM Unite! campaign. My name is Connie Popp. On May 8, 2015, my husband Ted passed away after a 5 year …
FDA Approves Opdivo and Yervoy Combination for Advanced Melanoma
September 30, 2015Statement from Tim Turnham, Executive Director, Melanoma Research Foundation The Melanoma Research Foundation (MRF) applauds the FDA’s approval of the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for patients with previ …
Recent Comments